InflaRx Plans Two Phase 2 Izicopan Trials in ANCA-Associated Vasculitis in 2027

• InflaRx plans two Phase 2 izicopan trials in ANCA-associated vasculitis starting in 2027, with first results expected in 2028.
• A placebo-controlled trial will assess kidney benefits; an open-label study will test whether izicopan can replace corticosteroids safely.
• An independent commercial assessment estimates izicopan's peak sales potential at $1.5 billion to $2 billion in ANCA-associated vasculitis.
• Additional kidney-disease studies target initial atypical hemolytic uremic syndrome data in late 2027, followed by IgA nephropathy data in 2028.
• Cash, cash equivalents and marketable securities totaled €153.3 million on September 30, 2026, with funding expected to support operations through 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030700PRIMZONEFULLFEED9868976) on November 03, 2026, and is solely responsible for the information contained therein.